Skip to main content
SpringerLink
Log in

Thalamotomy for Parkinson’s Disease

  • Chapter
Modern Stereotactic Neurosurgery

Part of the book series: Topics in neurological surgery ((TINS,volume 1))

Abstract

Despite the significant impact of dopamine replacement and other adjuvant medical therapies on the lives of patients with Parkinson’s disease, the role of surgery in this disorder has gained renewed interest [32, 57]. To evaluate the position surgical therapy should hold in the treatment of Parkinson’s disease symptoms, it is necessary to understand the incidence, etiology, pathology, and natural history, of the disorder and to weigh the benefits and complications of both medical and surgical therapies. This chapter reviews the literature and examines the long-term results in patients with Parkinson’s disease who have been treated at the University of Zurich. The indications for surgical therapy are reviewed and reconsidered in light of these current findings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Ballard PA, Tetrud JW, Langston JW: Permanent human parkinsonism due to MPTP: Seven Cases. Neurology 35: 949–956, 1985

    PubMed  CAS  Google Scholar 

  2. Barbeau A: L-dopa therapy in Parkinson’s disease: A critical review of nine years’ experience. Can Med Assoc J 101: 791–800, 1969

    Google Scholar 

  3. Barbeau A, Pourcher E: New data on the genetics of Parkinson’s disease. Can J Neurol Sci 9: 53–66, 1982

    PubMed  CAS  Google Scholar 

  4. Bergmann KJ, Mendoza MR, Yahr MD: Parkinson’s disease and long-term levodopa therapy. Presented at the VIIIth International Symposium on Parkinson’s Disease, June 9–12, 1985, New York, NY

    Google Scholar 

  5. Bernheimer H, Birkmayer W, Hornykiewicz O, et al: Brain dopamine and the syndromes of parkinsonism and Huntington: Clinical, morphological and neurochemical correlation. J Neurol Sci 20: 415–455, 1973

    Article  PubMed  CAS  Google Scholar 

  6. Bienchne JR: Drugs for Parkinson’s disease, spasticity, and acute muscle spasms. In Gilman AG, Goodman LS, Rall TW, et al (eds): The Pharmacological Basis of Therapeutics. New York: Macmillan, 1985, pp 473–490

    Google Scholar 

  7. Birkmayer W, Danielczyk W, Riederer P: Symptoms and side effects in the course of Parkinson’s disease. J Neural Transm [Suppl] 19: 185–199, 1983

    CAS  Google Scholar 

  8. Birkmayer W, Reiderer P, Youdin JBH: Distinction between benign and malignant types of Parkinson’s disease. Clin Neurol Neurosurg 81: 158–164, 1979

    Article  PubMed  CAS  Google Scholar 

  9. Blume E: Street drugs yield Parkinson’s model. JAMA 250: 13–14, 1983

    Article  PubMed  CAS  Google Scholar 

  10. Burns RS, Chiuch CC, Markey SP, et al: A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by MPTP. Nat Acad Sci USA 80: 4546–4550, 1983

    Article  CAS  Google Scholar 

  11. Calne DB: Progress in Parkinson’s disease. N Engl J Med 310: 523–524, 1984

    Article  PubMed  CAS  Google Scholar 

  12. Calne DB, Langston JW: Aetiology of Parkinson’s disease. Lancet 2: 1457–1459, 1984

    Google Scholar 

  13. Cooper IS: Neurosurgical treatment of dyskinesias. Clin Neurosurg 24: 367–390, 1977

    PubMed  CAS  Google Scholar 

  14. Cotzias GS, Papavasiliou PS, Tolosa ES, et al: Treatment of parkinsonism with apomorphines: Possible role of growth hormone. N Engl J Med 294: 567–572, 1976

    Article  PubMed  CAS  Google Scholar 

  15. Da Prada M, Keller HH, Pieri L, et al: The pharmacology of Parkinson’s disease: Basic aspects and recent advances. Experientia 40: 1165–1172, 1984

    Article  PubMed  Google Scholar 

  16. Ehringer H, Hornykiewicz O: Verteilung von noradrenalin und dopamin im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin Wochenschr 38: 1236–1239, 1960

    Article  PubMed  CAS  Google Scholar 

  17. Forno LS: The Lewy body in Parkinson’s disease. Presented at the VIIIth International Symposium on Parkinson’s Disease, June 9–12, 1985, New York, NY

    Google Scholar 

  18. Gilroy J, Meyer JS: Medical Neurolgy ( 2nd ed ). New York: Macmillan, 1975

    Google Scholar 

  19. Harada H, Nishikawa S, Takahashi K: Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol 40: 151–154, 1983

    PubMed  CAS  Google Scholar 

  20. Hoehn M: Parkinsonism treated with levodopa: Progression and mortality. J Neural Transm [Suppl] 19: 253–264, 1983

    Google Scholar 

  21. Hoehn M: Parkinson’s disease: progression and mortality. Presented at the VIIIth International Symposium on Parkinson’s Disease, June 9–12, 1985, New York, NY

    Google Scholar 

  22. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression and mortality. Neurology 17: 427–442, 1967

    PubMed  CAS  Google Scholar 

  23. Hornykiewicz O: Biochemical abnormalities in some extrastriatal neuronal systems in Parkinson’s disease. In Rinne UK, Klingler M, Stamm G (eds): Parkinson’s Disease: Current Progress, Problems and Management. Amsterdam: Elsevier, Biomedical Press, 1980, pp 109–119

    Google Scholar 

  24. Hornykiewicz O: Current concepts and controversies in Parkinson’s disease. (Symposium) Can J Neurol Sci 11 (Suppl 1): 89–240, 1984

    Google Scholar 

  25. Jankovic J: Long-term study of pergolide in Parkinson’s disease. Neurology 35: 296–299, 1985

    PubMed  CAS  Google Scholar 

  26. Joseph C, Chassan JB, Koch ML: Levodopa in Parkinson’s disease. Ann Neurol 227: 75–88, 1982

    Google Scholar 

  27. Jovoy-Agid F, Agid Y: Is the mesocortical dopaminergic system involved in Parkinson’s disease? Neurology 30: 1326–1330, 1980

    Google Scholar 

  28. Kelly PJ, Gillingham FJ: The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson’s disease. J Neurosurg 53: 332–337, 1980

    Article  PubMed  CAS  Google Scholar 

  29. Kocher U, Siegfried J, Perret E: Verbal and nonverbal learning ability of Parkinson patients before and after unilateral ventrolateral thalamotomy. Appl Neurophysiol 45: 311–316, 1982

    PubMed  CAS  Google Scholar 

  30. Kurland LT, Kurtzke JF, Goldberg ID: Epidemiology of neurologic and sense organ disorders. Cambridge, MA: Harvard University Press, 1973, pp 41–63

    Google Scholar 

  31. Kurland R, Miller C, Lewy R, et al: Long-term experience with pergolide therapy of advanced parkinsonism. Neurology 35: 738–742, 1985

    Google Scholar 

  32. Laitinen LV: Brain targets in surgery for Parkinson’s disease. J Neurosurg 62: 349–351, 1985

    Article  PubMed  CAS  Google Scholar 

  33. Langston JW, Ballard PA, Tetrud JW: Chronic parkinsonism in humans due to nine products of meperidine-analog synthesis. Science 219: 979–980, 1983

    Article  PubMed  CAS  Google Scholar 

  34. Langston JW, Forno LS, Robert CS, et al: Selective nigral toxicity after systemic administration of MPTP in the squirrel monkey. Brain Res 292: 390–394, 1984

    Article  PubMed  CAS  Google Scholar 

  35. Lesser RP, Fahn S, Snider SR, et al: Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253–1260, 1979

    PubMed  CAS  Google Scholar 

  36. Manen J, Speelman JD, Tans KJJ: Indications for surgical treatment of Parkinson’s disease after levodopa therapy. Clin Neurol Neurosurg 86: 207–212, 1984

    Article  PubMed  Google Scholar 

  37. Mann DMA, Yates PD: Possible role of neuromelanin in the pathogenesis of Parkinson’s disease. Mech Ageing Dev 21: 193–203, 1983

    Article  PubMed  CAS  Google Scholar 

  38. Martin WE, Young WI, Anderson VE: Parkinson’s disease: A genetic study. Brain 96: 495–506, 1973

    Article  PubMed  CAS  Google Scholar 

  39. Marttila RJ: Etiology of Parkinson’s disease. In Rinne UK, Klingler M, Stamm G (eds): Parkinson’s Disease: Current Progress, Problems, and Management. Amsterdam: Elsevier, Biomedical Press, 1980, pp 3–16

    Google Scholar 

  40. Marttila RJ, Rinne UK: Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson’s disease: A case control study. Clin Neurol Neurosurg 79: 45–56, 1976

    Article  Google Scholar 

  41. Marttila RJ, Rinne UK: Epidemiology of Parkinson’s disease: An overview. J Neural Transm 51: 135–148, 1981

    Article  PubMed  CAS  Google Scholar 

  42. Matsumoto K, Shichijo F, Fukami T: Longterm follow-up review of cases of Parkinson’s disease after unilateral or bilateral thalamotomy. J Neurosurg 60: 1033–1044, 1984

    Article  PubMed  CAS  Google Scholar 

  43. Mortimer JA, Pirozzola FJ, Hansch EC, et al: Relationship of motor symptoms to intellectual defects in Parkinson’s disease. Neurology 32: 133–137, 1982

    PubMed  CAS  Google Scholar 

  44. Narabayashi H, Yokochi F, Nakajima): Levodopa-induced dyskinesia and thalamotomy. J Neurol Neurosurg Psychiatrÿ 47: 831–839, 1984

    Article  PubMed  CAS  Google Scholar 

  45. Ohye C, Hirai T, Miyazaki M, et al: thalamotomy for the treatment of various kinds of tremor. App/ Neurophysiol 45: 275–280, 1982

    CAS  Google Scholar 

  46. Oppenheimer DR: Diseases of the basal ganglia, cerebellum and motor neurons. In Greenfield’s Pathology ( 3rd ed ). New York: Wiley, 1976, pp 608–651

    Google Scholar 

  47. Price KS, Farley IJ, Hornykiewicz O: Neurochemistry of Parkinson’s disease: relation between striatal and limbic dopamine. In Roberts PJ, Woodruff GM, Iversen LL (eds): Advances in Biomedical Psychopharmacology, Vol 19. New York: Raven Press, 1978, pp 293–300

    Google Scholar 

  48. Rajput AG, Offord KP, Beard CM, et al: Epidemiology of parkinsonism: Incidence, classification, and mortality. Ann Neurol 16: 278–282, 1984

    Article  PubMed  CAS  Google Scholar 

  49. Riechert T: Stereotaxic surgery for treatment of Parkinson’s syndrome. Prog Neurol Surg 5: 178, 1973

    Google Scholar 

  50. Riechert T, Mundinger F: Beschreibung and anwendung eines Zielgeraetes for stereotaktische hirnoperationen (II. Model). Acta Neurochir [Suppl] (Wien) 308: 337, 1955

    Google Scholar 

  51. Rinne UK, Sonninen V, Siirtola T, et al: Longterm responses of Parkinson’s disease to levodopa therapy. J Neural Transco [Suppl] 16: 149–156, 1980

    Google Scholar 

  52. Scatton B, Ronguier L, Jovoy-Agid F, et al: Dopamine deficiency in the cerebral cortex in Parkinson’s disease. Neurology 32: 1039–1040, 1982

    PubMed  CAS  Google Scholar 

  53. Schoenberg BS, Anderson DW, Haerer AF: Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 35: 841–845, 1985

    PubMed  CAS  Google Scholar 

  54. Selby G: The influence of previous stereotactic thalamotomy on L-dopa therapy in Parkinson’s disease. Proc Aust Assn Neurol 13: 55–60, 1976

    CAS  Google Scholar 

  55. Siegfried J: Deux and d’experience avec la L-dopa associeé a un inhibiteur de la decarboxylase. Rev Neurol (Paris) 122: 243–248, 1970

    CAS  Google Scholar 

  56. Siegfried J: Is the neurosurgical treatment of Parkinson’s disease still indicated? J Neural Transm [Suppl] 16: 195–198, 1980

    Google Scholar 

  57. Siegfried J: Neurosurgical treatment of Parkinson’s disease. Present indications and value. In Rinne UK, Klingler M, Stamm G (eds): Parkinson’s Disease: Current Progress, Problems and Management, North Holland: Elsevier, Biomedical Press, 1980, pp 369–376

    Google Scholar 

  58. Siegfried J: Die Parkinsonsche Krankheit und ihre Behandlung, Vol 1. Wien, New York: Springer Verlag, 1968, p 262

    Google Scholar 

  59. Siegfried J: The place of L-dopa in the treatment of Parkinson’s disease. Progr Neurol Surg 5: 387–405, 1973

    Google Scholar 

  60. Siegfried J, Brandli-Graber S: Repérage radiologique simple du trou de Monro sur les radiographies crâniennes à vide. Neurochirurgie 26: 387–389, 1980

    PubMed  CAS  Google Scholar 

  61. Siegfried J, Hood T: Current status of functional neurosurgery. In Krayenbuhl H (ed): Advances and Technical Standards in Neurosurgery,Vol 10. New York: Springer-Verlag, 1983, pp 19— 79

    Google Scholar 

  62. Siegfried J, Klaiber R, Perret E, et al: Treatment of Parkinson’s disease with L-dopa and a decarboxylase inhibitor. German Medical Monthly 15: 315–318, 1970

    Google Scholar 

  63. Siegfried J, Zumstein H: Thalamotomies stereotaxiques pour troubles fonctionnels chez les personnes agees. Neurochirurgie 22: 536–539, 1976

    PubMed  CAS  Google Scholar 

  64. Svennilson E, Torvik A, Lower R, et al: Treatment of parkinsonism by stereotactic thermolesions in the pallidal region: A clinical evaluation of 81 cases. Acta Psychiatr Neurol Scand 35: 358–377, 1960

    Article  CAS  Google Scholar 

  65. Sweet RD, McDowell FH: Five years’ treatment of Parkinson’s disease with levodopa: Therapeutic results and survival of 100 patients. Ann Intern Med 83: 456–486, 1975

    PubMed  CAS  Google Scholar 

  66. Tasker RR, Organ LW, Hawrylyshyn P: Investigation of the surgical target for alleviation of involuntary movement disorders. Appl Neurophysiol 45: 261–274, 1982

    PubMed  CAS  Google Scholar 

  67. Turner B: Pathology of paralysis agitans. In Vinken PJ, Bruyn GW (eds): Diseases of the Basal Ganglia. Handbook of Clinical Neurology, Vol 6. Amsterdam-North Holland, 1968, pp 212–217

    Google Scholar 

  68. Uhl GR, Hedreen JC, Price DL: Parkinson’s disease: Loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 35: 1215–1218, 1985

    PubMed  CAS  Google Scholar 

  69. Ward CD, Duvoisin RC, Ince SE, et al: Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology 33: 815–824, 1983

    PubMed  CAS  Google Scholar 

  70. Yahr MD: Overview of present day treatment of Parkinson’s disease. J Neural Transm 43: 227–238, 1978

    Article  PubMed  CAS  Google Scholar 

  71. Zetusky WJ, Jankovic J, Pirozzola FJ: The hetrogeneity of Parkinson’s disease: clinical and prognostic implications. Neurology 35: 522–526, 1985

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Jean Siegfried
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. L. Rea
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    L. Dade Lunsford M.D. (Associate Professor of Neurological Surgery and Radiology, Chief) (Associate Professor of Neurological Surgery and Radiology, Chief)

  2. Stereotactic and Functional Surgery, Presbyterian-University Hospital, Pittsburgh, Pennsylvania, USA

    L. Dade Lunsford M.D. (Associate Professor of Neurological Surgery and Radiology, Chief) (Associate Professor of Neurological Surgery and Radiology, Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Siegfried, J., Rea, G.L. (1988). Thalamotomy for Parkinson’s Disease. In: Lunsford, L.D. (eds) Modern Stereotactic Neurosurgery. Topics in neurological surgery, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1081-5_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1081-5_25

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8418-5

  • Online ISBN: 978-1-4613-1081-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation